# PTPRK

Source: https://onco.cc/targets/ptprk/  
OnCo record `ptprk` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PTPRK (Receptor-type tyrosine-protein phosphatase kappa) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Bladder & urothelial cancer, Renal cell carcinoma and 5 more.

## Summary

Regulation of processes involving cell contact and adhesion such as growth control, tumour invasion, and metastasis. Negative regulator of EGFR signalling pathway. Forms complexes with beta-catenin and gamma-catenin/plakoglobin.

Open Targets scores its association with cancer at 0.72 (direct and indirect evidence; datatypes literature 0.93, animal model 0.59, genetic association 0.50, somatic mutation 0.85). IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Bladder Urothelial Carcinoma, Renal Clear Cell Carcinoma, Non-Small Cell Lung Cancer.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: protein tyrosine phosphatase receptor type K; Receptor-type tyrosine-protein phosphatase kappa; R-PTP-kappa
- Tags: cancer-genes-wave
- Symbol: PTPRK
- Class: enzyme
- Biology: Regulation of processes involving cell contact and adhesion such as growth control, tumour invasion, and metastasis. Negative regulator of EGFR signalling pathway. Forms complexes with beta-catenin and gamma-catenin/plakoglobin. Beta-catenin may be a substrate for the catalytic activity of PTPRK/PTP-kappa. Location: Cell junction, adherens junction; Cell membrane (UniProt). Locus 6q22.33 (HGNC).
- Where found: Breast cancer: Open Targets association 0.57 with breast cancer (MONDO_0007254); Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA); Renal cell carcinoma: IntOGen driver in 1 cohort (CCRCC); Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898); Colorectal cancer: Open Targets association 0.55 with colorectal cancer (MONDO_0005575); Melanoma: Open Targets association 0.58 with melanoma (MONDO_0005105)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:9674: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9674
- UniProt Q15262: https://www.uniprot.org/uniprotkb/Q15262/entry
- NCBI Gene 5796: https://www.ncbi.nlm.nih.gov/gene/5796
- Ensembl ENSG00000152894: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000152894

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Clear cell renal cell carcinoma](https://onco.cc/cancers/clear-cell-rcc/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/ptprk.json